Upendra Marathi | Chief Executive Officer
7 Hills Pharma LLC
Upendra Marathi, PhD, MBA is the CEO and a co-founder of 7 Hills Pharma. He is an inventor of their first-in-concept technology and a significant investor in the company. He has led the development of three novel pain and cardiovascular drugs, including one recently approved by the FDA. He co-developed one of the first genetically modified stem cells to improve bone marrow function in chemotherapeutic patients. As a venture capitalist, he was involved in the founding and launch of several biotechnology companies. He has helped raise over $64 million in equity financing. Upendra was a post-doctoral fellow at St. Jude Children’s Research Hospital and M.D. Anderson Cancer Center, and earned a Ph.D. in Pharmacology from Loyola University Chicago. Upendra has an M.B.A. from Rice University and has served as a faculty member.
Appearances:
WVIC/WAC Pre-Congress Workshops - Nov 28 @ 14:00
Workshop A [Room: Constellation A]
2pm: Chair opening remarks: Rebecca Kurnat M.S., Head of Product, SaponiQx
Presentations: 2.10pm – 4.00pm:
Using synthetic biology in adjuvant technology & creating a pipeline of vaccine adjuvants
Dr John Baldoni, Head of Science, SaponiQx
Next generation TLR agonists & RIG-I as adjuvants
Dr Steve Reed, CEO, HDT Bio
An oral adjuvant to augment vaccine effectiveness
Dr Upendra Marathi, President & CEO, 7Hills Pharma
Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation
Dr Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research, LaJolla Institute for Immunology
4.00-5:00pm Q&A and Panel Discussion with all speakers
- What are the limitations of current adjuvants?
- Importance of unique formulations & combination adjuvants
- Kinetics, localization, dose sparing
- Ensuring a secure supply of known adjuvants
- Rapid response and stockpiling
- Emerging concepts in adjuvant science
- What mechanisms are required to advance vaccines?
- Novel adjuvant technology – synthetic adjuvants
- Development of an adjuvant pipeline – can new adjuvants rescue previously failed vaccines?
- What factors drive clinical failure?
WVIC/WAC Day 1 - Nov 29 @ 17:20
7HP349, an integrin agonist to overcome resistance to immune checkpoint blockade
For conference programme and speaking opportunities:
Lauren Sheppard
lauren.sheppard@terrapinn.com
For sponsorship and exhibition opportunities:
Thomas Hall
thomas.hall@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events